Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial
Research output: Contribution to journal › Journal article › Research › peer-review
Dendritic cells are regarded as the most effective antigen presenting cells and coordinators of the immune response and therefore suitable as vaccine basis. Here we present results from a clinical study in which patients with malignant melanoma (MM) with verified progressive disease received vaccination with autologous monocyte-derived mature dendritic cells (DC) pulsed with p53, survivin and telomerase-derived peptides (HLA-A2+ patients) or with autologous/allogeneic tumor lysate (HLA-A2(-) patients) in combination with low-dose interleukin (IL)-2 and interferon (IFN)-alpha2b.
Original language | English |
---|---|
Journal | Cytotherapy |
Volume | 12 |
Issue number | 6 |
Pages (from-to) | 721-34 |
Number of pages | 14 |
ISSN | 1465-3249 |
DOIs | |
Publication status | Published - 1 Oct 2010 |
ID: 32304621